Timolol 0.5% ophthalmic — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Primary Open-Angle Glaucoma

• Brimonidine
• Latanoprost
• Brimonidine 0.2% ophthalmic
• Latanoprost 0.005% ophthalmic

About Timolol 0.5% ophthalmic

Timolol 0.5 ophthalmic solution is a widely prescribed eye drop used to manage elevated eye pressure, a key factor in glaucoma. Understanding your medication and how to afford it is crucial. With TheDrugClub, members can access essential prescriptions like Timolol 0.5 for a $0 co-pay, delivered right to your door, making vision care both simple and budget-friendly.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Timolol 0.5% ophthalmic is approved for (FDA label)

Timolol Maleate Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Timolol Maleate Ophthalmic Solution is a beta adrenergic blocker indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: November 4, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Timolol 0.5% ophthalmic (FDA label)

Ophthalmic solution containing 0.5% (5 mg/mL) of timolol (6.8 mg/mL of timolol maleate). Ophthalmic solution containing timolol 0.5% (5 mg/mL) ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: b686bbad-1ef7-4b94-a316-4d182a40b89a. SPL document ID: 261bb64e-88e2-1585-e063-6394a90aeaf4. Label effective date: November 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Timolol 0.5% ophthalmic (FDA label)

The most frequently reported adverse reactions have been burning and stinging upon instillation in 38% of patients treated with Timolol Maleate Ophthalmic Solution. Additional reactions reported with Timolol Maleate Ophthalmic Solution at a frequency of 4% to 10% include: blurred vision, cataract, conjunctival injection, headache, hypertension, infection, itching and decreased visual acuity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: b686bbad-1ef7-4b94-a316-4d182a40b89a. SPL document ID: 261bb64e-88e2-1585-e063-6394a90aeaf4. Label effective date: November 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Timolol 0.5% ophthalmic (FDA label)

Bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease ( 4.1 , 5.1 , 5.3 ) Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock ( 4.2 , 5.2 ) Hypersensitivity to any component of this product ( 4.3 ) 4.1 Asthma, COPD Timolol Maleate Ophthalmic Solution is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease [see Warnings and Precautions ( 5.1 , 5.3 )] . 4.2 Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock Timolol Maleate Ophthalmic Solution is contraindicated in patients with sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock [see Warnings and Precautions ( 5.2 )] . 4.3 Hypersensitivity Reactions Timolol Maleate Ophthalmic Solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this product in the past. 4.1 Asthma, COPD Timolol

Source: FDA prescribing information (DailyMed). Set ID: b686bbad-1ef7-4b94-a316-4d182a40b89a. SPL document ID: 261bb64e-88e2-1585-e063-6394a90aeaf4. Label effective date: November 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Timolol 0.5% ophthalmic (FDA label)

Potentiation of Respiratory Reactions Including Asthma ( 5.1 ) Cardiac Failure ( 5.2 ) Obstructive Pulmonary Disease ( 5.3 ) Increased Reactivity to Allergens ( 5.4 ) Potentiation of Muscle Weakness ( 5.5 ) Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus ( 5.6 ) Masking of Thyrotoxicosis ( 5.7 ) 5.1 Potentiation of Respiratory Reactions Including Asthma Timolol Maleate Ophthalmic Solution contains timolol maleate; and although administered topically, it can be absorbed systemically. Therefore, the same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration.

Source: FDA prescribing information (DailyMed). Set ID: b686bbad-1ef7-4b94-a316-4d182a40b89a. SPL document ID: 261bb64e-88e2-1585-e063-6394a90aeaf4. Label effective date: November 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Timolol 0.5% ophthalmic (FDA label)

Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. ( 7.1 ) Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. ( 7.2 ) Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia. ( 7.3 ) Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. ( 7.4 ) Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with quinidine and timolol. ( 7.5 ) 7.1 Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and Timolol Maleate Ophthalmic Solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.

Source: FDA prescribing information (DailyMed). Set ID: b686bbad-1ef7-4b94-a316-4d182a40b89a. SPL document ID: 261bb64e-88e2-1585-e063-6394a90aeaf4. Label effective date: November 4, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.